Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -80.96% is 219% below its 5-year average of -25.38%, near the low end of its 5-year range (-80.96%–17.07%).
As of the fiscal period ended Tuesday, June 30, 2026. 37.27% below its 12-month average of -58.98%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): -80.96%.
RETURN ON EQUITY (ROE)
-80.96%
RETURN ON EQUITY (ROE) AVG TTM
-58.98%
RETURN ON EQUITY (ROE) AVG 3Y
-35.06%
RETURN ON EQUITY (ROE) AVG 5Y
-25.38%
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
-37.27%
CURRENT VS 3Y AVG
-130.89%
CURRENT VS 5Y AVG
-219.04%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-42.01%
median of 753 covered companies
CURRENT VS SECTOR MEDIAN
-92.72%
vs the sector median at left
Atea Pharmaceuticals, Inc.
Market Cap
$405.74M
Return on Equity (ROE)
-80.96%
TTM Avg
-58.98%
3Y Avg
-35.06%
5Y Avg
-25.38%
Market Cap
$406.58M
Return on Equity (ROE)
-69.06%
TTM Avg
36.89%
3Y Avg
36.89%
5Y Avg
36.89%
Market Cap
$404.24M
Return on Equity (ROE)
-37.05%
TTM Avg
-58.80%
3Y Avg
-40.96%
5Y Avg
-32.01%
Market Cap
$402.17M
Return on Equity (ROE)
-51.17%
TTM Avg
-29.16%
3Y Avg
-33.45%
5Y Avg
-16.04%
Market Cap
$411.00M
Return on Equity (ROE)
14.40%
TTM Avg
1.26%
3Y Avg
-7.83%
5Y Avg
-9.02%
Market Cap
$411.21M
Return on Equity (ROE)
-65.99%
TTM Avg
-51.25%
3Y Avg
-81.12%
5Y Avg
-81.12%
Market Cap
$397.99M
Return on Equity (ROE)
-43.14%
TTM Avg
2.19%
3Y Avg
15.11%
5Y Avg
15.11%
Market Cap
$396.93M
Return on Equity (ROE)
-28.18%
TTM Avg
-0.06%
3Y Avg
10.58%
5Y Avg
10.58%
Market Cap
$415.98M
Return on Equity (ROE)
-77.06%
TTM Avg
-61.48%
3Y Avg
-56.03%
5Y Avg
-55.28%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Atea Pharmaceuticals, Inc. (AVIR) | $405.74M | -80.96% | -58.98% | -35.06% | -25.38% |
| Eikon Therapeutics, Inc. Common Stock (EIKN)vs › | $406.58M | -69.06% | 36.89% | 36.89% | 36.89% |
| Myriad Genetics, Inc. (MYGN)vs › | $404.24M | -37.05% | -58.80% | -40.96% | -32.01% |
| Neurogene Inc. (NGNE)vs › | $402.17M | -51.17% | -29.16% | -33.45% | -16.04% |
| Strata Critical Medical, Inc. (SRTA)vs › | $411.00M | 14.40% | 1.26% | -7.83% | -9.02% |
| MapLight Therapeutics, Inc. (MPLT)vs › | $411.21M | -65.99% | -51.25% | -81.12% | -81.12% |
| Carlsmed, Inc. (CARL)vs › | $397.99M | -43.14% | 2.19% | 15.11% | 15.11% |
| Shoulder Innovations, Inc. (SI)vs › | $396.93M | -28.18% | -0.06% | 10.58% | 10.58% |
| Rezolute, Inc. (RZLT)vs › | $415.98M | -77.06% | -61.48% | -56.03% | -55.28% |
| Senseonics Holdings, Inc. (SENS)vs › | $416.27M | -121.12% | 180.84% | -1331.02% | -839.91% |
ROE
-81.0%
ROA
-71.2%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | -80.96% |
| 2026-03-31 | -72.53% |
| 2025-12-31 | -57.49% |
| 2025-09-30 | -46.56% |
| 2025-06-30 | -37.35% |
| 2025-03-31 | -33.93% |
| 2024-12-31 | -38.37% |
| 2024-09-30 | -37.95% |
| 2024-06-30 | -36.94% |
| 2024-03-31 | -32.45% |
| 2023-12-31 | -24.49% |
| 2023-09-30 | -22.56% |
| 2023-06-30 | -17.62% |
| 2023-03-31 | -17.68% |
| 2022-12-31 | -18.09% |
| 2022-09-30 | 5.38% |
| 2022-06-30 | 2.35% |
| 2022-03-31 | 7.12% |
| 2021-12-31 | 17.07% |
| 2021-09-30 | 4.25% |
| 2021-06-30 | 5.90% |
| 2021-03-31 | 4.05% |
| 2020-12-31 | -2.00% |
| 2020-09-30 | -36.54% |
| 2020-06-30 | -19.77% |
| 2020-03-31 | -100.54% |
| 2019-12-31 | -71.81% |
